Mural Oncology PLC (NASDAQ:MURA) Given Consensus Recommendation of “Hold” by Brokerages

by · The Cerbat Gem

Mural Oncology PLC (NASDAQ:MURA – Get Free Report) has been given a consensus rating of “Hold” by the five analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $12.00.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mural Oncology in a report on Monday, December 8th.

Read Our Latest Research Report on MURA

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Shay Capital LLC acquired a new stake in shares of Mural Oncology during the third quarter worth $93,000. Quadrature Capital Ltd bought a new position in Mural Oncology during the second quarter worth about $98,000. Virtu Financial LLC bought a new position in Mural Oncology during the third quarter worth about $115,000. Rangeley Capital LLC acquired a new stake in Mural Oncology in the 2nd quarter worth about $115,000. Finally, BML Capital Management LLC bought a new stake in Mural Oncology in the 3rd quarter valued at about $119,000. 80.21% of the stock is owned by institutional investors and hedge funds.

Mural Oncology Stock Performance

Mural Oncology stock opened at $2.04 on Wednesday. The stock has a 50-day simple moving average of $2.07 and a 200 day simple moving average of $2.18. The stock has a market capitalization of $35.38 million, a P/E ratio of -0.29 and a beta of 2.93. Mural Oncology has a 52 week low of $0.95 and a 52 week high of $4.74.

Mural Oncology (NASDAQ:MURA – Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.38. Research analysts forecast that Mural Oncology will post -7.54 earnings per share for the current year.

Mural Oncology Company Profile

(Get Free Report)

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.

Recommended Stories